logo-loader
viewFSD Pharma

FSD Pharma finalizes US$17.5M acquisition of R&D pharma company Prismic Pharmaceuticals

FSD Pharma also has agreed to assume approximately US$3.05 million of outstanding Prismic long- and short-term liabilities

medical cannabis
FSD Pharma grows medical-grade cannabis at its 25,000 square foot facility in Ontario, with an additional 220,000 expected to be added by the end of 2019

FSD Pharma Inc (CSE: HUGE) (OTCMKTS:FSDDF) announced Tuesday it has closed on the deal to acquire US-based specialty research and development pharma company Prismic Pharmaceuticals Inc.

The Canadian company, which grows medical-grade cannabis, has acquired all outstanding shares of Prismic for about US$17.5 million (C$23.4 million), to be satisfied by the issuance of 102.7 million Class B subordinate voting shares in FSD Pharma at a price of US$0.1704 (C$0.2275) per FSD share.

READ: FSD Pharma granted full sales license from Health Canada to supply and distribute medicinal cannabis

In addition, FSD Pharma has agreed to assume approximately US$3.05 million of Prismic's long and short-term liabilities. All of the outstanding Prismic stock options and warrants have been converted into options and warrants to purchase FSD shares, with the number and exercise price of such securities having been adjusted in accordance with the exchange ratio under the agreement.

The FSD shares issued to the former Prismic shareholders were deposited into escrow, and are subject to an 18-month staggered release.

FSD Pharma will continue to be led by CEO Dr Raza Bokhari. Zachary Dutton, co-founder of Worcester, Massachusetts-based Prismic, will continue to serve as the CEO of Prismic, reporting to Dr Edward Brennan Jr, president of the FSD Biosciences Division.

Peter Moriarty, co-founder and previous chairman of the board of Prismic, has been named chairman of the newly-formed FSD BioPharmaceutical Industry Advisory Board.

Eyeing synthetic cannabinoid prescription medications

“The Prismic acquisition represents strategic depth in the vision and mission of FSD Pharma and signals a paradigm shift in the overall outlook of the company,” said Bokhari. “We are relying heavily on the expertise of Dr Brennan, who is a seasoned pharmaceutical industry veteran with substantial experience from working at Glaxo Smith Kline and Johnson & Johnson to navigate us through the various stages of the FDA approval process for drug development.”

Bokhari noted that it’s the company’s goal to make “synthetic cannabinoid prescription medications available for commercial use to help alleviate the pain and suffering of patients.”

FSD Pharma is headquartered at the former Kraft plant in Cobourg, Ontario in a large facility that sits on 72 acres of land. It grows medical-grade cannabis at its 25,000 square foot facility in Ontario, with an additional 220,000 expected to be added by the end of 2019.

The company intends to target all aspects of the cannabis industry: cultivation, processing, manufacturing, extracts and research and development.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: FSD Pharma

Price: 5.26 CAD

CSE:HUGE
Market: CSE
Market Cap: $41.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: FSD Pharma 'hunkering down' on grow facility and 'doubling...

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) CEO Raza Bokhari reveals 3Q highlights for the medically-focused cannabis company. Bokhari says the Canadian company is 'hunkering down' on its cannabis grow facility and 'doubling down' on its biosciences effort, advancing its Phase 1 safety trials...

1 week ago

3 min read